Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients with Tuberculosis

Carlos A. Rodriguez, Andres F. Zuluaga, Michael N. Neely, Yamile Sierra, Jessica Morales-Gutierrez, Julian Zapata, Juan D. Zapata, Tonny W. Naranjo, Yuli Agudelo

    Research output: Contribution to journalArticlepeer-review

    2 Scopus citations

    Abstract

    Background:Isoniazid (INH) is a first-line antituberculosis (TB) agent with a pharmacokinetic profile characterized by high interindividual variation; however, population pharmacokinetic studies in patients with TB are scarce. The aim was to develop a population model for INH in Colombian patients with TB suitable for predicting drug exposure and assessing the probability of target attainment of pharmacodynamic goals.Methods:Ten hospitalized adult patients with TB undergoing INH treatment were recruited. After an 8-hour fasting, subjects took 300 mg of INH, and 10 samples were taken from 0 to 12 hours. INH was quantified by high-performance liquid chromatography-UV, and data were analyzed with the Pmetrics R package software. A Monte Carlo simulation with the model parameters was run to determine the probability of target attainment for optimal efficacy.Results:The best model included 2 compartments, first-order absorption (Ka), delayed absorption (Tlag), and linear clearance (CL). Median Tlag was 0.25 hours, 5.54 hour-1 for Ka, for CL, for the volume of the central compartment (Vc), 1.04 L/h for intercompartmental clearance (Q), and 788 L for the volume of the peripheral compartment (Vp). CL and Vc were allometrically scaled on basis of the normalized body weight.Conclusions:The Monte Carlo simulation indicated that 300 mg of INH per day is appropriate for Mycobacterium tuberculosis strains with minimal inhibitory concentration (MIC) up to 0.03 mg/L (target: area under the concentration-time curve/MIC >597); however, to cover strains with MIC up to 0.125 mg/L (80% of clinical isolates), a dose of 900 mg per day would be required.

    Original languageEnglish
    Pages (from-to)719-725
    Number of pages7
    JournalTherapeutic Drug Monitoring
    Volume41
    Issue number6
    DOIs
    StatePublished - 1 Dec 2019

    Bibliographical note

    Funding Information:
    Supported by the University of Antioquia, Hospital Universitario San Vicente Fundacion and Sistema general de Regalias de Colombia, Ruta N, Gobernacion de Antioquia (BPIN 2013000100183).

    Publisher Copyright:
    © 2019 Wolters Kluwer Health, Inc.

    Keywords

    • antitubercular drugs
    • INH
    • pharmacokinetics
    • TB

    Fingerprint

    Dive into the research topics of 'Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients with Tuberculosis'. Together they form a unique fingerprint.

    Cite this